x
Filter:
Filters applied
- JTO: Editors Choice
- NivolumabRemove Nivolumab filter
- ImmunotherapyRemove Immunotherapy filter
Publication Date
Please choose a date range between 2016 and 2018.
Author
- Adeni, Anika E1
- Awad, Mark M1
- Baas, Paul1
- Buikhuisen, Wieneke1
- Burgers, Sjaak1
- Cheng, Matthew P1
- Costa, Daniel B1
- Disselhorst, Maria1
- Faig, Jennifer1
- Fujita, Kohei1
- Hammond, Sarah P1
- Hartemink, Koen1
- Huberman, Mark S1
- Klomp, Houke1
- Lalezari, Ferry1
- Leonardi, Giulia C1
- Lydon, Christine A1
- Marty, Francisco M1
- Mio, Tadashi1
- Monkhorst, Kim1
- Ostios-Garcia, Lorena1
- Quispel-Janssen, Josine1
- Rangachari, Deepa1
- Schouten, Robert1
- Schunselaar, Laurel1
Editors Choice
3 Results
- Original Article MesotheliomaOpen Access
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Journal of Thoracic OncologyVol. 13Issue 10p1569–1576Published online: June 13, 2018- Josine Quispel-Janssen
- Vincent van der Noort
- Jeltje F. de Vries
- Marion Zimmerman
- Ferry Lalezari
- Erik Thunnissen
- and others
Cited in Scopus: 160Malignant pleural mesothelioma (MPM) has limited treatment options and a poor outcome. Programmed death 1/programmed death ligand 1 (PD-L1) checkpoint inhibitors have proven efficacious in several cancer types. Nivolumab is a fully humanized monoclonal antibody against programmed death 1 with a favorable toxicity profile. In MPM, the immune system is considered to play an important role. We therefore tested nivolumab in recurrent MPM. - Brief ReportOpen Archive
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer
Journal of Thoracic OncologyVol. 13Issue 7p1037–1042Published online: April 6, 2018- Lorena Ostios-Garcia
- Jennifer Faig
- Giulia C. Leonardi
- Anika E. Adeni
- Safiya J. Subegdjo
- Christine A. Lydon
- and others
Cited in Scopus: 69Despite widespread administration of programmed death receptor 1 (PD-1) pathway inhibitors among individuals with NSCLC, little is known about the safety and activity of these agents among human immunodeficiency virus (HIV) – infected patients since this population has largely been excluded from immunotherapy clinical trials. - Brief Report
Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Journal of Thoracic OncologyVol. 11Issue 12p2238–2240Published online: July 13, 2016- Kohei Fujita
- Tsuyoshi Terashima
- Tadashi Mio
Cited in Scopus: 99Recently, cancer immunotherapy by immune checkpoint inhibitors has been considered one of the pillars for the treatment of cancer. Nivolumab is the first immune checkpoint inhibitor approved for lung cancer treatment in Japan. Although nivolumab has superior survival benefits and fewer adverse events than cytotoxic agents, it can generate dysimmune toxicities, known as immune-related adverse events. Although autoimmune manifestations are well-known immune-related adverse events, the development of infectious diseases is rare.